Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Oct;53(10):854–855. doi: 10.1136/jnnp.53.10.854

Platelet monoamine oxidase B activity in parkinsonian patients.

U Bonuccelli 1, P Piccini 1, P Del Dotto 1, G M Pacifici 1, G U Corsini 1, A Muratorio 1
PMCID: PMC488245  PMID: 2266365

Abstract

Monoamine oxidase B (MAO B) plays a pivotal role in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinsonism. An increased MAO B activity in platelets of patients with idiopathic Parkinson's disease (PD) is reported in this study. The possibility that high MAO B activity may represent a trait of vulnerability for PD by enhancing the neurotoxic effects of environmental compounds is discussed.

Full text

PDF
854

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belendiuk K., Belendiuk G. W., Freedman D. X., Antel J. P. Neurotransmitter abnormalities in patients with motor neuron disease. Arch Neurol. 1981 Jul;38(7):415–417. doi: 10.1001/archneur.1981.00510070049006. [DOI] [PubMed] [Google Scholar]
  2. Belmaker R. H., Ebbesen K., Ebstein R., Rimon R. Platelet monoamine oxidase in schizophrenia and manic-depressive illness. Br J Psychiatry. 1976 Sep;129:227–232. doi: 10.1192/bjp.129.3.227. [DOI] [PubMed] [Google Scholar]
  3. Calne D. B., Eisen A., McGeer E., Spencer P. Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet. 1986 Nov 8;2(8515):1067–1070. doi: 10.1016/s0140-6736(86)90469-1. [DOI] [PubMed] [Google Scholar]
  4. D'Amato R. J., Zweig R. M., Whitehouse P. J., Wenk G. L., Singer H. S., Mayeux R., Price D. L., Snyder S. H. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol. 1987 Aug;22(2):229–236. doi: 10.1002/ana.410220207. [DOI] [PubMed] [Google Scholar]
  5. Danielczyk W., Streifler M., Konradi C., Riederer P., Moll G. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand. 1988 Dec;78(6):730–736. doi: 10.1111/j.1600-0447.1988.tb06412.x. [DOI] [PubMed] [Google Scholar]
  6. Del Zompo M., Bernardi F., Bonuccelli U., Maggio R., Bajorek M., Arnone M., Corsini G. U. Properties of 3H-MPTP binding sites in human blood platelets. Life Sci. 1986 Nov 17;39(20):1885–1891. doi: 10.1016/0024-3205(86)90299-7. [DOI] [PubMed] [Google Scholar]
  7. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  8. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  10. Houslay M. D., Tipton K. F. Multiple forms of monoamine oxidase: fact and artefact. Life Sci. 1976 Aug 15;19(4):467–477. doi: 10.1016/0024-3205(76)90224-1. [DOI] [PubMed] [Google Scholar]
  11. Javitch J. A., Uhl G. R., Snyder S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4591–4595. doi: 10.1073/pnas.81.14.4591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  13. Lee D. H., Mendoza M., Dvorozniak M. T., Chung E., van Woert M. H., Yahr M. D. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. J Neural Transm Park Dis Dement Sect. 1989;1(3):189–194. doi: 10.1007/BF02248668. [DOI] [PubMed] [Google Scholar]
  14. Lloyd K. G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975 Dec;195(3):453–464. [PubMed] [Google Scholar]
  15. Mann J. J., Stanley M., Kaplan R. D., Sweeney J., Neophytides A. Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1983 Oct;46(10):905–910. doi: 10.1136/jnnp.46.10.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mohamed M. K., Burbacher T. M., Mottet N. K. Effects of methyl mercury on testicular functions in Macaca fascicularis monkeys. Pharmacol Toxicol. 1987 Jan;60(1):29–36. doi: 10.1111/j.1600-0773.1987.tb01715.x. [DOI] [PubMed] [Google Scholar]
  17. Pletscher A. Platelets as models: use and limitations. Experientia. 1988 Feb 15;44(2):152–155. doi: 10.1007/BF01952200. [DOI] [PubMed] [Google Scholar]
  18. Yong V. W., Perry T. L. Monoamine oxidase B, smoking, and Parkinson's disease. J Neurol Sci. 1986 Feb;72(2-3):265–272. doi: 10.1016/0022-510x(86)90014-6. [DOI] [PubMed] [Google Scholar]
  19. Youdim M. B. Platelet monoamine oxidase B: use and misuse. Experientia. 1988 Feb 15;44(2):137–141. doi: 10.1007/BF01952197. [DOI] [PubMed] [Google Scholar]
  20. Zeller E. A., Boshes B., Arbit J., Bieber M., Blonsky E. R., Dolkart M., Huprikar S. V. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. J Neural Transm. 1976;39(1-2):63–77. doi: 10.1007/BF01248766. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES